Amarin is building a strong patent portfolio around Vascepa, which is good because the company will need every last bit of protection to bolster its inevitable legal case against generic challenges. If Amarin fails to gain NCE status, the odds increase that the company is forced to launch Vascepa on its own, without a major pharmaceutical partner or a buyer of the entire company. Wall Street investors aren't going to like a solo Vascepa launch at all. P.S. Those Amarin insider sales right after Vascepa's approval in late July look even more timely today. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.